Literature DB >> 2247708

Cryptococcal meningitis in the acquired immunodeficiency syndrome.

L A Panther1, M A Sande.   

Abstract

Cryptococcosis is the most common, deep-seated fungal infection in AIDS patients, and cryptococcal meningitis is the most frequently observed syndrome. AIDS patients with cryptococcal meningitis usually have an indolent presentation and nonspecific findings on physical examination. Routine laboratory tests are of little assistance in diagnosing cryptococcal meningitis. Cerebrospinal fluid (CSF) white blood cell counts tend to be low, and glucose and protein levels are nonspecific. Serum cryptococcal antigen (CRAG) is a sensitive test for cryptococcal meningitis, and CSF CRAG is usually also positive. Definitive diagnosis is made by culture of the CSF. Therapy of cryptococcal meningitis is changing to antifungal agents that are easy to administer as outpatient therapy. Amphotericin B continues to be the primary antifungal used in initial treatment of cryptococcal meningitis; addition of flucytosine is of no benefit. Recent data suggest oral fluconazole is effective as primary therapy, and may be superior to amphotericin B as maintenance therapy. Maintenance therapy decreases the incidence of relapse and increases survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2247708

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  5 in total

1.  Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; L A Klug; W S Baughman; D Rimland; E A Graviss; R J Hamill; C Thomas; P G Pappas; A L Reingold; R W Pinner
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

2.  In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.

Authors:  M C Cruz; M S Bartlett; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting.

Authors:  K A Haynes; D J Sullivan; D C Coleman; J C Clarke; R Emilianus; C Atkinson; K J Cann
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

4.  Multilocus enzyme typing of Cryptococcus neoformans.

Authors:  M E Brandt; S L Bragg; R W Pinner
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

5.  Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. The Cryplococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; R J Kuykendall; R W Pinner
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.